Adicet Bio, Inc. (ACET) grants 18,300 stock options to Chief Medical Officer
Rhea-AI Filing Summary
Adicet Bio, Inc. reported that its Chief Medical Officer, Klickstein Lloyd, received a grant of stock options covering 18,300 shares of common stock at an exercise price of $9.16 per share. According to the award terms, 1/6th of the options vest on each of the next six monthly anniversaries of August 5, 2026, subject to continued service, and the options expire on August 4, 2036.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Klickstein Lloyd
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 18,300 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 18,300 shares (Direct)
Footnotes (1)
- F1. 1/6th of the shares subject to this option shall vest and become exercisable on each of the next six (6) monthly anniversaries of August 5, 2026, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting dates.
Key Figures
Stock options granted: 18,300 shares
Exercise price: $9.16 per share
Expiration date: August 4, 2036
+1 more
4 metrics
Stock options granted
18,300 shares
Stock Option (Right to Buy) granted to Klickstein Lloyd on August 5, 2026
Exercise price
$9.16 per share
Exercise price for the 18,300 stock options granted
Expiration date
August 4, 2036
Expiration of the stock options granted to Klickstein Lloyd
Vesting schedule
1/6th monthly over six months
1/6th vests on each of the next six monthly anniversaries of August 5, 2026
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for the reported grant"
exercise price financial
"conversion_or_exercise_price: "9.1600" indicating the exercise price per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this option shall vest and become exercisable on each of the next six"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: "2036-08-04" specifying the option’s expiration date"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock option grant did ACET’s Chief Medical Officer receive?
Klickstein Lloyd received a grant of 18,300 stock options, each for one share of Adicet Bio common stock, with an exercise price of $9.16 per share. The options are classified as a “Stock Option (Right to Buy)” and were granted on August 5, 2026.
When do Klickstein Lloyd’s new ACET stock options vest?
The options vest in six equal installments, with 1/6th of the shares vesting on each of the next six monthly anniversaries of August 5, 2026. Vesting is explicitly conditioned on the reporting person’s continued service with Adicet Bio on each applicable vesting date.
What is the exercise price and term of the new ACET options?
The stock options have an exercise price of $9.16 per share and an expiration date of August 4, 2036. This gives the holder the right to buy Adicet Bio common stock at $9.16 per share until that expiration date, subject to vesting.
Is the new ACET option grant a direct holding for Klickstein Lloyd?
Yes. The filing identifies the ownership of these 18,300 stock options as direct. Following this grant, total stock options held in this award are 18,300, reflecting the full amount of the newly granted, unexercised options reported for Klickstein Lloyd.